Using systems pharmacology, we identified 50 anti‐HCC core targets, including EGFR, c‐Myc, ERBB2, ESR1, CCND1, and HSP90AA1, all of which play critical roles in tumor initiation, proliferation, angiogenesis, and resistance mechanisms [23, 47, 48, 49, 50, 51, 52, 53]. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.